 | • レポートコード：MRC2203A768 • 出版社/出版日：Mordor Intelligence / 2022年1月 • レポート形態：英文、PDF、112ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医薬品 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Site Licence | ￥962,000 (USD6,500) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査資料では、世界の抗炎症薬市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、治療別（関節炎、慢性閉塞性肺疾患（COPD）、多発性硬化症、炎症性腸疾患（IBD）、喘息）分析、薬剤分類別（抗炎症生物製剤、非ステロイド性抗炎症薬（NSAIDS）、コルチコステロイド、免疫選択性抗炎症誘導体（ImSAID）、その他）分析、販売チャネル別（処方、OTC）分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）分析、競争状況、市場機会・将来の傾向などの項目を掲載しています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の抗炎症薬市場規模：治療別（関節炎、慢性閉塞性肺疾患（COPD）、多発性硬化症、炎症性腸疾患（IBD）、喘息） ・世界の抗炎症薬市場規模：薬剤分類別（抗炎症生物製剤、非ステロイド性抗炎症薬（NSAIDS）、コルチコステロイド、免疫選択性抗炎症誘導体（ImSAID）、その他） ・世界の抗炎症薬市場規模：販売チャネル別（処方、OTC） ・世界の抗炎症薬市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争状況（Pfizer Inc.、Amgen Inc.、GlaxoSmithKline PLC、...） ・市場機会・将来の傾向 |
Anti-inflammatory drugs are the drugs that are used to treat conditions like Asthma, Arthritis, Chronic obstructive pulmonary disease (COPD) and other diseases. Increasing prevalence of these diseases is the major factor propelling the market upwards. Although documented incidences of side effects and patent expiration of Blockbuster drugs are restraining the market growth, new research advancements in Anti Inflammatory Biologics, Immune Selective Anti-Inflammatory Derivatives (ImSAIDs), etc. are helping to make this class of drugs as side effect free as possible, maintaining the efficacy and potency of the drug.
Moreover, increasing awareness of anti-inflammatory therapeutics and attractive government initiatives are expected to drive the overall market.
Key Market Trends
Anti Inflammatory Drugs for Arthritis Treatment is Found Dominating the Market
Arthritis is the inflammation in the joints. There are different types of arthritis, osteoarthritis and rheumatoid arthritis being most common among them. Arthritis is found to be more prevalent in the geriatric population, but there have been some documented cases of arthritis in children as well. Other common forms of arthritis include psoriatic arthritis, fibromyalgia and gout.
Osteoarthritis is caused due to the breakdown of protective cartilage, causing pain and movement of joints difficult. Non-steroidal Anti-Inflammatory drugs (NSAIDs) like diclofenac, ibuprofen and naproxen have been proven to be very effective in suppressing the pain from Osteoarthritis but may cause side effects like stomach upset, cardiovascular problems, bleeding problems, and liver and kidney damage. NSAID gels have also been proven to alleviate the pain and have lesser side effects. Doctors have been turning towards prescribing newest form of Anti-Inflammation drugs called Biologics.
The risk of arthritis has only increased in recent times due to an increase in the sedentary lifestyle, obesity, and unhealthy food habits. Hence, the drug market for its treatment will only see growth in recent future.
North America is Expected to Dominate the Anti-Inflammatory Drugs Market
North America is the largest market in the Anti-Inflammatory Drugs Market due to the factors such as established healthcare sector with a large number of renowned players, high investment & demand for more effective and safer drugs, etc. Moreover, the high income per capita, rise in patient visits to physicians, research advancements due to high funding are some of the factors that are driving the growth of the North American market.
However, Asia Pacific is expected to emerge as the fastest market, driven by a vast patient pool, increasing disposable incomes, growth in healthcare spending, and rising awareness about health.
Competitive Landscape
Majority of the Anti-Inflammatory drugs are being manufactured by the global key players. Market leaders with more funds for research and better distribution system have established their position in the market.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Incidences of Autoimmnue and Respiratory Conditions
4.2.2 Growing Research for Safer New Anti-Inflammatory Drugs
4.3 Market Restraints
4.3.1 Side Effects of Anti-Inflammtory Drugs
4.3.2 Patent Expiration
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Treatment
5.1.1 Arthritis
5.1.2 Chronic obstructive pulmonary disease (COPD)
5.1.3 Multiple Sclerosis
5.1.4 Inflammatory bowel disease (IBD)
5.1.5 Asthma
5.1.6 Tendonitis
5.1.7 Other Treatments
5.2 By Drug Class
5.2.1 Anti-Inflammatory Biologics
5.2.2 Nonsteroidal anti inflammatory drugs (NSAIDS)
5.2.3 Corticosteroids
5.2.4 Immune-selective anti-inflammatory derivative (ImSAID)
5.2.5 Other Drug Classes
5.3 By Sales Channel
5.3.1 Prescription
5.3.2 Over the Counter (OTC)
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Pfizer Inc.
6.1.2 Amgen Inc.
6.1.3 GlaxoSmithKline PLC
6.1.4 Johnson & Johnson
6.1.5 Novartis AG
6.1.6 F. Hoffmann-La Roche AG
6.1.7 AbbVie Inc
6.1.8 AstraZeneca PLC
6.1.9 Merck & Company, Inc.
6.1.10 Eli Lily and Company
7 MARKET OPPORTUNITIES AND FUTURE TRENDS